|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.44 EUR | +1.42% |
|
+0.06% | -3.61% |
Sanofi and Regeneron Pharmaceuticals Inc. said there are about 75,000 adults in the U.S. living with prurigo nodularis who are most in need of a new treatment option. "Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease," at 6:50 p.m. ET Sept. 28, incorrectly said the companies said there are about 75,000 adults in the U.S. living with prurigo nodularis.
(END) Dow Jones Newswires
09-30-22 1456ET
| 1st Jan change | Capi. | |
|---|---|---|
| -3.61% | 113B | |
| +27.97% | 672B | |
| +23.95% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.13% | 211B | |
| -0.38% | 203B | |
| -10.06% | 194B | |
| -11.81% | 144B |
SANOFI 
